Mengzhong Liu

机构：Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China · ORCID：0000-0001-7463-4514

发表论文 120 篇 · 总被引 4272 次 · h-index 27

代表论文

• Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial (2023 · The Lancet Oncology · 被引 105)
• A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901) (2023 · EClinicalMedicine · 被引 51)
• Predictive role of ctDNA in esophageal squamous cell carcinoma receiving definitive chemoradiotherapy combined with toripalimab (2024 · Nature Communications · 被引 34)
• Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: Results from the phase III trial NEOCRTEC5010 (2022 · Journal of Thoracic and Cardiovascular Surgery · 被引 26)
• Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis (2022 · BMC Cancer · 被引 24)
• Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy (2023 · The Oncologist · 被引 17)